Abstract | BACKGROUND: METHODS AND RESULTS: Treatment effects on low- and high-density lipoprotein particle number (by NMR) and Lp-PLA2 (by ELISA) were evaluated using plasma samples available from 358 subjects in the study. Switching to ES10/20 reduced low-density lipoprotein-particle number numerically more than did statin dose-doubling and was comparable with R10 (-133.3, -94.4, and -56.3 nmol/L, respectively; P>0.05). Increases in high-density lipoprotein particle number were significantly greater with switches to ES10/20 versus statin dose-doubling (1.5 and -0.5 μmol/L; P<0.05) and comparable with R10 (0.7 μmol/L; P>0.05). Percentages of patients attaining low-density lipoprotein particle number levels <990 nmol/L were 62.4% for ES10/20, 54.1% for statin dose-doubling, and 57.0% for R10. Switching to ES10/20 reduced Lp-PLA2 activity significantly more than did statin dose-doubling (-28.0 versus -3.8 nmol/min per mL, P<0.05) and was comparable with R10 (-28.0 versus -18.6 nmol/min per mL; P>0.05); effects on Lp-PLA2 concentration were modest. CONCLUSIONS: CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00862251.
|
Authors | Ngoc-Anh Le, Joanne E Tomassini, Andrew M Tershakovec, David R Neff, Peter W F Wilson |
Journal | Journal of the American Heart Association
(J Am Heart Assoc)
Vol. 4
Issue 10
Pg. e001675
(Oct 20 2015)
ISSN: 2047-9980 [Electronic] England |
PMID | 26486166
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2015 The Authors. [Ngoc‐Anh Le and Peter W. F. Wilson] and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. |
Chemical References |
- Biomarkers
- Ezetimibe, Simvastatin Drug Combination
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Lipoproteins
- 1-Alkyl-2-acetylglycerophosphocholine Esterase
- PLA2G7 protein, human
|
Topics |
- 1-Alkyl-2-acetylglycerophosphocholine Esterase
(blood)
- Aged
- Biomarkers
(blood)
- Cardiovascular Diseases
(diagnosis, etiology)
- Diabetes Mellitus, Type 1
(complications, diagnosis)
- Diabetes Mellitus, Type 2
(complications, diagnosis)
- Double-Blind Method
- Drug Substitution
- Dyslipidemias
(blood, complications, diagnosis, drug therapy)
- Europe
- Ezetimibe, Simvastatin Drug Combination
(administration & dosage, adverse effects)
- Female
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, adverse effects)
- Lipoproteins
(blood)
- Male
- Middle Aged
- Risk Factors
- South America
- Time Factors
- Treatment Outcome
- United States
|